J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
Zacks.com on MSN1mon
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaFollowing this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...
Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development.
In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback